Key Highlights

  • Shares declined 18.63% to USD 5.24 in pre-market trading on November 3, 2026.
  • Third quarter 2026 Revenue reached USD 110.0 million, down 52% from USD 231.1 million.
  • The net loss stood at USD 32.7 million, or USD 0.64 per diluted share.
  • Full-year 2026 revenue guidance was lowered to USD 600 million to USD 645 million.
  • Naloxone product sales dropped 42% to USD 43.5 million.

Pre-Market Slide After the Earnings Release (down USD 1.20, 18.63%)

Emergent BioSolutions (NYSE:EBS) slid 18.63% to USD 5.24 in pre-market trading on November 3, 2026, measured against the Monday close. The drop followed third quarter results released on November 2, 2026, which showed a steep revenue decline and a weaker full-year outlook.

Inside the Quarterly Results

According to a company press release dated November 2, 2026, total revenue for the quarter ended September 30, 2026 came to USD 110.0 million, versus USD 231.1 million a year earlier. The company reported a net loss of USD 32.7 million, compared with Net Income of USD 51.2 million in the prior-year quarter. Adjusted EBITDA was a loss of USD 4.6 million, compared with a profit of USD 92.6 million.

Naloxone sales, covering NARCAN and KLOXXADO, totaled USD 43.5 million, down from USD 74.9 million, mainly due to lower U.S. over-the-counter NARCAN sales. Smallpox countermeasure sales fell to USD 26.7 million from USD 83.6 million, which the company mostly attributed to U.S. government timing. Anthrax countermeasure sales increased to USD 25.1 million from USD 1.4 million on higher CYFENDUS sales.

Guidance and Company Background

Emergent, headquartered in Gaithersburg, Maryland, focuses on biodefense medical countermeasures and a naloxone portfolio. The company cut 2026 revenue guidance to USD 600 million to USD 645 million from USD 645 million to USD 675 million. Adjusted EBITDA guidance declined to USD 110 million to USD 140 million from USD 130 million to USD 150 million, while adjusted gross Margin guidance was raised to 45% to 47%.

The company also said its chief financial officer will retire effective December 31, 2026, with the treasurer becoming interim chief financial officer on January 1, 2027. It described a multi-year transformation with priorities that include paying down debt.

Balance Sheet and Risks

The release did not disclose cash or total Debt balances, but it said the company completed the repurchase of USD 75 million in aggregate principal of its senior unsecured notes. Interest expense is assumed at about USD 38 million for 2026.

Shares can move sharply on thin pre-market volume. Revenue from government contracts can shift with order timing, and over-the-counter naloxone sales have been weaker, so quarterly results may remain uneven.

What to Watch Next

Key items include the timing of U.S. government orders, naloxone sales trends, progress on debt reduction and the search for a permanent finance chief. Opening trading Volume will show whether the pre-market decline lasts in the regular session.